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Lineage mapping has identified both proliferative
and quiescent intestinal stem cells, but themolecular
circuitry controlling stem cell quiescence is incom-
pletely understood. By lineage mapping, we show
Lrig1, a pan-ErbB inhibitor, marks predominately
noncycling, long-lived stem cells that are located at
the crypt base and that, upon injury, proliferate and
divide to replenish damaged crypts. Transcriptome
profiling of Lrig1+ colonic stem cells differs markedly
from the profiling of highly proliferative, Lgr5+ colonic
stem cells; genes upregulated in the Lrig1+ popula-
tion include those involved in cell cycle repression
and response to oxidative damage. Loss of Apc in
Lrig1+ cells leads to intestinal adenomas, and genetic
ablation of Lrig1 results in heightened ErbB1-3
expression and duodenal adenomas. These results
shed light on the relationship between proliferative
and quiescent intestinal stem cells and support a
model in which intestinal stem cell quiescence is
maintained by calibrated ErbB signaling with loss of
a negative regulator predisposing to neoplasia.
INTRODUCTION
Mechanisms that regulate homeostasis in the highly dynamic,
continuously self-renewing small and large (colonic) intestinal
epithelia are not fully elucidated. In particular, there is consider-
able debate about the nature of stem and progenitor cells within146 Cell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc.these tissues. Based primarily upon radiation-response studies,
intestinal stem cells (ISCs) were long thought to be relatively
quiescent, capable of becoming more mitotically active to repo-
pulate crypts in response to epithelial damage (Potten, 1998).
Long-term lineage tracing has identified Lgr5, Bmi1, mTert,
and Hopx (Barker et al., 2007; Montgomery et al., 2011; San-
giorgi and Capecchi, 2008; Takeda et al., 2011; Tian et al.,
2011) as bona fide ISC markers. Bmi1+ and mTert+ cells reside
at position four from the crypt base, are largely quiescent, and
exhibit a steep gradient of expression from the proximal to distal
intestine. The finding that Lgr5 marks a distinctive, highly prolif-
erative population of small intestinal and colonic stem cells (SCs)
has challenged the existence of quiescent SCs. However, Tian
et al. (2011) recently demonstrated that Bmi1+ cells give rise to
Lgr5+ cells and can substitute for Lgr5+ cells when Lgr5+ cells
are eliminated in the small intestine. These investigators noted
the lack of Bmi1 expression in the colon and suggested another,
yet undefined, SC population may be important when Lgr5+ cells
are lost in the colon.
To identify and characterize colonic SC markers with known
functions, we performed gene expression profiling of CD24-puri-
fiedmouse colonic epithelial progenitor cells (Akashi et al., 1994;
Gracz et al., 2010) and identified the Leucine-rich repeats and
immunoglobulin-like domains 1 (Lrig1) gene. Lrig1 is a transmem-
brane protein that acts as an inducible, negative feedback
inhibitor of ErbB signaling (Laederich et al., 2004). Lrig1 has
been suggested to mark a multipotent and quiescent SC popu-
lation in mammalian epidermis, although lineage tracing was not
performed (Jensen et al., 2009; Jensen and Watt, 2006). Lrig1
null mice develop psoriasis, a hyperproliferative disorder of the
skin (Suzuki et al., 2002), suggesting that Lrig1 is important for
themaintenance of tissues that undergo continuous self-renewal
Figure 1. Lineage Tracing in the Small Intestine
and Colon Confirms Lrig1 Marks SCs
(A–C) Generation of Lrig1-CreERT2/+mice. (A) Schematic
representation of the Lrig1-CreERT2 targeting vector. A
tamoxifen-inducible Cre (CreERT2) was targeted into the
translational initiation site of the endogenous Lrig1 locus.
Southern blot analysis of embryonic SCs with 30, 50, and
internal neo probes confirmed the correct integration at
a frequency of 8.7% (B and data not shown). Chimeras
were mated with FlpE mice to achieve germline trans-
mission and neo cassette removal. The resulting hetero-
zygous and homozygous mice were viable and fertile. (C)
Lrig1-CreERT2 animals were genotyped by specific
Lrig1-CreERT2 PCR.
(D–K) Low-power view of Lrig1-CreERT2/+;R26RLacZ/+
lineage-labeled small intestine at different time points
following a single i.p. injection of 2 mg tamoxifen (D0–G0).
Representative sections of high-power view of b-gal+
small intestine (D1–G1). Low-power view of Lrig1-
CreERT2/+;R26RLacZ/+ lineage-labeled colon at different
time points following a single i.p. injection of 2 mg
tamoxifen (H0–K0). Representative sections of high-
power view of b-gal+ colonic crypts (H1–K1).
The scale bars represent 100 mm (D0 and H0), 200 mm
(E0–G0 and I0–K0), 50 mm (D1–G1), and 25 mm (H1–K1).
See also Figure S1 and Tables S1 and S2.and may serve to suppress growth in those tissues. In addition,
LRIG1 mRNA and protein expression are downregulated in
a number of solid tumors (Ljuslinder et al., 2007; Miller et al.,
2008; Thomasson et al., 2003; Ye et al., 2009).
In this study, we show that Lrig1 marks a subset of ISCs that
are relatively quiescent under homeostatic conditions but are
mobilized upon tissue damage to repopulate the colonic crypt.
Whole-transcriptome analysis of Lrig1+ and Lgr5+ colonic
epithelial cells reveals significant differences in the molecular
programs of the two cell populations. We also show that lossCell 149,of Apc in Lrig1+ cells results in multiple intes-
tinal adenomas and the largest tumors are
found in the distal colon. In addition, we demon-
strate that Lrig1 null mice develop duodenal
adenomas, providing in vivo evidence that the
ErbB negative regulator Lrig1 functions as a
tumor suppressor. Taken together, these results
underscore the importance of calibrated ErbB
signaling in the ISC niche and the neoplastic
consequences of perturbing this regulation.
RESULTS
Lineage Tracing Reveals that Lrig1 Marks
ISCs
Based on Lrig1 expression in CD24-sorted
mouse colonocytes (data not shown) and immu-
nohistochemical detection in quiescent SCs in
the epidermis (Jensen et al., 2009), we sought
to determine whether Lrig1 marked ISCs. We
generated an Lrig1 knockin allele, into which
a tamoxifen-inducible form of Cre recombinase(CreERT2) (Feil et al., 1997) was targeted by homologous recom-
bination to the translational start site of the endogenous Lrig1
locus (Lrig1-CreERT2; Figures 1A–1C and Tables S1 and S2,
available online). Lineage tracing was performed by intercross-
ing Lrig1-CreERT2 and R26RLacZ mice (Soriano, 1999).
Lrig1-CreERT2/+;R26RLacZ/+ (hereafter Lrig1 reporter) mice
received one intraperitoneal (i.p.) injection of 2 mg tamoxifen.
The small intestine and colon were stained in whole mount for
b-galactosidase (b-gal) activity over time (Figures 1D0–1K1),
where b-gal reporter reflects Lrig1 mRNA expression. One day146–158, March 30, 2012 ª2012 Elsevier Inc. 147
Figure 2. Analysis of Lrig1 Reporter Mice
(A) One day after tamoxifen induction, 50%of small intestinal crypts and 40% of colonic crypts are labeled. At 90 days, the number of labeled crypts decreases to
18% in the small intestine and 10% in the colon.
(B and C) Frequency of b-gal activity at different positions relative to the small intestinal (B) and colonic (C) crypt base one day after tamoxifen administration.
(D–I) Costaining with various differentiation markers to confirm multipotency of progeny of cells that exhibit b-gal activity: Mucin2 (Muc 2) marks goblet cells (D
and G); Chromogranin-A (Chr A) marks enteroendocrine cells (E and I); Lysozyme (Lys) marks Paneth cells (F); and Carbonic Anhydrase IV (CAIV) marks en-
terocytes (H).
(J–Q) Whole-mount view of Lrig1-CreERT2/+;R26RLacZ/+ (J–M) and Lgr5-EGFP-IRES-CreERT2;R26RLacZ/+ lineage-labeled intestines (N–Q).
The error bars represent standard error of the mean (SEM). The scale bars represent 25 mm (D–I) and 500 mm (J–Q). See also Figure S2.after tamoxifen induction, over 50%of small intestinal and40%of
colonic crypts were labeled (Figure 2A). Most labeled crypts con-
tained one or two cells which exhibited b-gal activity, virtually all
of which were at the bottom one-third of crypts (Figures 1D1
and 1H1 and 2B and 2C and high-power images in Figures S1A
and S1B). However, some cells were located further up in the
crypts, as indicated in Figures2Band2C.Sevendaysafter induc-
tion, staining for b-gal activity wasmorewidespread (Figures 1E0
and 1E1 compared to 1D0 and 1D1, and 1I0 and 1I1 compared to
1H0 and 1H1) as initially tagged cells proliferated and generated
progeny which displayed b-gal activity. At 14 days after injection,
both fully and partially labeled crypts and villi were observed
(Figures 1F0 and 1F1 and 1J0 and 1J1). At 90 days, 18% of small
intestinal and 10%of colonic cryptswere entirely lineage-labeled
(Figures 1G0 and 1G1 and 1K0 and 1K1, and 2A and Figure S1C)
and contained the differentiated cell lineages of the small intes-
tine and colon (Figures 2D–2I). Labeled crypts remained entirely148 Cell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc.b-gal reactive and accounted for up to 20% of total crypts up to
6.5 months (data not shown), providing definitive evidence that
Lrig1 marks intestinal SCs. Lrig1 lineage tracing also detected
short-term (24 hr) and long-term (two months) labeled cells in
the gastric epithelium and skin (Figures S1D and S1E); studies
are underway to characterize these progenitor cell populations.
We next compared lineage tracing of Lrig1 reporter mice to
Lgr5-EGFP-IRES-CreERT2; R26RLacZ/+mice. Using the induc-
tion scheme published for these Lgr5 reporter mice (Barker et al.,
2007), we observed a markedly greater number of lineage-
labeled crypts along the length of the intestine at three months
in Lrig1 reporter mice (Figures 2J–2Q and Figure S2) compared
to the Lgr5 reporter mice, demonstrating a clear difference in
the ability of these Cre drivers to efficiently label intestinal epithe-
lial SCs. It is important to note lineage tracing studies indicate
where the targeted gene is transcribed and do not necessarily
reflect protein production.
Figure 3. Expression Patterns of Lrig1 and
Lgr5 in Adult Mouse Colon by Immunofluo-
rescence and FACS
(A and B) Immunofluorescent detection and con-
focal microscopy of cross-sections in Lgr5-EGFP-
IRES-CreERT2 mouse colon detected a subset of
Lrig1+ cells (red) present at the crypt base, distinct
from Lgr5+ cells (green).
(C) Relative position of Lrig1+ and Lgr5+ pop-
ulations by immunofluorescence for Lrig1 and
direct EGFP fluorescence of the Lgr5 reporter.
(D) FACS analysis of Lgr5-EGFP-IRES-CreERT2
mouse intestinal epithelial cells (n = 9); Lrig1 was
detected in 2.4% of total enterocytes and 4.8% of
total colonocytes. When EGFPhi was used as a
markerofLgr5expression,0.5%of totalenterocytes
and 0.2% of total colonocytes were Lgr5+;Lrig1+.
(E) A representative colonic crypt stained for Lrig1
(red) and Ki67 (white).
(F) Twenty-five percent of Lrig1+ cells also stained
withKi67,whereas75%of theLgr5+populationalso
stained with Ki67.
(G) BrdU incorporation, measured in Lrig1
mouse colonocytes by FACS. Lrig1+;BrdU+ cells
were not detected in uninjected mice; 7% of Lrig1+
colonocytes coexpressed BrdU 2 hr after injection
(n = 3). Mice injected daily for 5 days and examined
6 weeks later had 12% Lrig1+;BrdU+ colonocytes
(n = 3). LT indicates long-term, label-retaining
experiment.
The scale bars represent 25 mm (A, B, and E). The
error bars represent SEM. See also Figures S3
and S4.Lrig1 Marks a Distinct Population of Intestinal Stem
Cells
To examine protein expression directly, we generated an anti-
body to the Lrig1 ectodomain, validated specificity in Lrig1/
(Suzuki et al., 2002) colonic tissue (Figure S3A) and performed
immunostaining in Lgr5-EGFP-IRES-CreERT2 and wild-type
mice. We compared Lrig1 and Lgr5 expression, as Lgr5 is an
established SC marker in mouse colon. Because antibodies do
not exist to examine endogenous Lgr5, we relied on enhanced
green fluorescent protein (EGFP) fluorescence as a surrogate
marker of Lgr5 expression. In normal mouse colon, we observed
Lrig1 protein reproducibly decorates one to three cells at the
crypt base (Figures 3A and 3B and Figure S3B) and occasionally
cells higher up the crypt (Figure 3C). By immunofluorescent
confocal analysis of crypt cross-sections, as well as 3D imaging
of isolated crypts, crypts containing Lrig1+ and Lgr5+ cells were
observed less frequently than crypts containing cells expressing
either marker alone. Nevertheless, when both populations were
observed in the same crypt, colocalization of the two markers
rarely occurred in the same cell (Figure 3B and Figures S4A–4C).
To quantify the number of Lrig1+ cells in adult mouse colon, we
performed fluorescence-activated cell sorting (FACS) analysis
of single epithelial cell suspensions generated from isolated
Lgr5-EGFP-IRES-CreERT2 colonic crypts. We found 2.4%
(small intestine) and 4.8% (colon) of total cells expressed Lrig1
alone (Figure 3D), consistent with reports for the clonogenic pop-
ulation predicted to be present within the colon (Cai et al., 1997;
Hendry et al., 1992; Potten, 1998). When EGFP was used as anindicator of Lgr5 expression, 0.5% (small intestine) and 0.2%
(colon) of total cells expressed both Lgr5 and Lrig1 (Figure 3D),
reflecting how infrequently this double-positive population was
observed in tissue sections (Figures S4A–S4C). This, however,
may be an underestimate, given that EGFP expression may be
present less frequently than endogenous Lgr5 (Escobar et al.,
2011). Finally, we examined the position of Lrig1+ cells in Lgr5-
EGFP-IRES-CreERT2 mice and found both Lgr5+ and Lrig1+
cells were located primarily at positions 1–5 (Figure 3C).
Lrig1+ Cells Are Label Retaining and Slowly Cycling
We next examined the proliferative state of Lrig1+ cells. As previ-
ously reported (Barker et al., 2007), Lgr5 is expressed in elon-
gated, crypt base columnar cells, frequently positive for the
proliferative marker Ki67 (Figure S4D). Lrig1+ cells had a lower
proliferative index (25% Ki67 positive; Figures 3E and 3F and
Figure S4E) than Lgr5+ cells (75% Ki67 positive). To further
explore the quiescence of Lrig1+ cells, we performed both short-
and long-term bromodeoxyuridine (BrdU) labeling analyses.
First, wild-type mice were injected daily for 5 days with BrdU
(allowing for maximal BrdU incorporation as mouse intestinal
epithelium turns over once per week) and subsequently main-
tained for 6 weeks without injection. To quantitatively measure
label retention, Lrig1+;BrdU+ colonic epithelia were subjected
to FACS. Approximately 12% of Lrig1+ cells were BrdU+ (Fig-
ure 3G). If measured after 5 days of BrdU injection, but before
the 6 week chase, nearly 20% of Lrig1+ cells were BrdU+ (data
not shown). In separate experiments, wild-type mice wereCell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc. 149
Figure 4. Lrig1+ Cells Can Be Traced from Birth and Proliferate in
Response to Irradiation Damage
(A) Lrig1-CreERT2/+;R26RLacZ/+ mice injected with tamoxifen at postnatal
day 1 and sacrificed 6 weeks later, harbored single, b-gal+ label-retaining
colonocytes at the crypt base.
(B) Examination of b-gal in the p1 injected animals revealed 7% colonic crypts
(n = 2; 400 crypts/animal) were entirely b-gal+, whereas nearly 14% contained
single, b-gal+ label-retaining colonocytes at the crypt base.
(C) In long-term, tamoxifen-induced Lrig1-CreERT2/+;R26RLacZ/+ mice, 8%
of b-gal+ cells were single cells at the base of the colonic crypt.
(D and E) One week after irradiation damage, many colonic crypts contained
b-gal+ cells in clusters.
150 Cell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc.injected with BrdU, and colonic epithelia were analyzed 2 hours
later by FACS for Lrig1 and BrdU positivity. Approximately 7% of
Lrig1+ cells were BrdU+, consistent with the minority population
of Lrig1+ cells also being Ki67+ (Figure 3G) at a snapshot in time.
Our Ki67 and BrdU analyses reveal themajority of Lrig1+ cells are
infrequently cycling, although they appear more proliferative
than Bmi1 and mTert populations (Montgomery et al., 2011;
Tian et al., 2011).
Long-Lived, Individual Lrig1+ Cells Repopulate
Damaged Crypts
A notable finding from our long-term lineage tracing analysis in
adult Lrig1 reporter mice was that 8% of total colonic crypts
harbored single b-gal+ cells near the crypt base (Figures 4A and
4D and Figure S3C). After tamoxifen injection of Lrig1 reporter
miceatbirthandexaminationofcolonssixweeks later, thenumber
of crypts with single-positive cells increased to 14% (Figures 4A
and 4B). These results indicate that lineage tracing in the devel-
oping mouse differs from the adult; however, both approaches
yield single-labeled cell populations. In the adult, these long-lived,
singly labeledcells did not expressChromogranin-A (FiguresS4F–
S4H), which marks enteroendocrine cells (long-lived, differenti-
ated cells that can be present at the crypt base).
To test whether single b-gal+ cells were quiescent SCs, we
performed irradiation injury with the expectation that they would
divide and produce progeny to repair the damaged tissue. We
subjected long-term (six month) labeled Lrig1 reporter mice to
a single dose (8 Gy) of X-ray irradiation. In unirradiated, long-
term labeled control animals, b-gal labeling was observed in
single cells at the crypt base (Figure 4D) and, as expected, in fully
labeled crypts (Figure S3D). No b-gal staining was observed in
irradiated, wild-type animals without the Lrig1 reporter (Fig-
ure S3E). Four days after irradiation of Lrig1 reporter mice,
55% of b-gal+ cells stained with Ki67 (n = 3; Figure 4G; p =
0.003), whereas in unirradiated mice only 14% of single b-gal+
cells expressed Ki67. One week after irradiation, 12% of colonic
crypts contained b-gal+ clusters (n = 3), whereas in unirradiated
animals only 5% of crypts contained clusters (n = 2; Figures 4E
and 4F). This shift represented a significant increase in irradiated
animals (Figure 4F, p = 0.04), probably owing to increased prolif-
eration. The proliferative increase is expected on the basis of
published reports of proliferative indices of intestinal progenitor
cells during homeostasis and after irradiation injury (Potten,
1998; Potten and Grant, 1998). On the basis of these results,
we conclude that Lrig1+ cells exhibit proliferative heterogeneity
(Simons and Clevers, 2011), wherein a predominately quiescent
progenitor population can proliferate and give rise to daughter
cells under the appropriate stimulus.(F) Clusters of b-gal+ cells increased in animals subjected to irradiation. In
control (unirradiated) animals, 5% of colonic crypts contained b-gal+ clusters;
this number increased to 12% in irradiated animals.
(G) Examination of b-gal+ cells in control and irradiated Lrig1-CreERT2/+;
R26R-LacZ animals revealed that 14% of b-gal+ cells stained with the prolif-
erative marker Ki67 in control animals, whereas this number increased to 55%
in irradiated animals.
All scale bars represent 25 mm. The error bars represent SEM. See also Figures
S3 and S4.
Global Transcriptional Analysis of Lrig1+ and Lgr5+ Stem
Cells
By combined genetic and biochemical analyses (Figures 1, 2, 3,
and 4), Lrig1+ and Lgr5+ cells appear to be different, yet related,
cell populations. To better appreciate the similarities and differ-
ences in the two populations, we isolated Lgr5-EGFPhi and
Lrig1+ cells by FACS from 6- to 8-week-old Lgr5-EGFP-IRES-
CreERT2 colonic crypts for whole-transcriptome sequencing
(Figures 5A and 5B). The transcriptome sequencing identified
21,000 total genes, of which2,500 were significantly differen-
tially regulated (Table S3). Comparing the populations at a tran-
scriptional level revealed similarities related to epithelial biology
and stemness, as well as a number of key differences related to
the cell cycle and oxidative stress (Figure 5C and Table S3). Both
populations expressed similar levels of genes associated with
ISCs such asmTert, Prominin1, and Bmi1 (not reported to be ex-
pressed robustly in the colon; Figure 5B and Figure S5A), and
classic intestinal epithelial cell-associated genes, such as b-cat-
enin, E-cadherin, Keratin 8, Epithelial cell adhesion molecule,
Occludin, and Claudins 2 and 7 (Figure 5B and Figure S5A).
Notable differences between the two populations were also
observed. Lgr5 and Olfactomedin4 (Olfm4), a surrogate marker
for Lgr5+ cells (van der Flier et al., 2009), were underrepresented
in Lrig1+ cells but highly expressed in Lgr5+ cells (Figure 5B and
Figure S5A), validating that the EGFPhi sorted cell population
were true Lgr5+ cells, as reported (Barker et al., 2007). Consistent
with thedifferingcell cyclestatusof the twopopulations,anumber
of cell-cycle-promoting genes (PCNA, Axin2, Myc, and Cyclin-
dependent kinase4)weresignificantly enriched inLgr5+cells (Fig-
ure 5BandFigureS5A). Biological pathway analysis of Lgr5+ cells
revealed that one of the predominant programs in Lgr5+ cells is
cell cycle promotion (Figure 5C). Of note, expression of a recently
discovered marker of ISCs, Hopx (Takeda et al., 2011), is nearly
2-fold greater in Lgr5-EGFPhi cells than in Lrig1+ cells. In contrast,
Lrig1+ cells highly expressed Ly6a, or Sca-1, a hematopoietic SC
marker (Spangrude et al., 1988), aswell as the Egfr ligand amphir-
egulin (Areg; Figure 5B and 5C and Figure S5A). Importantly, the
cell cycle inhibitor Cdkn1a (p21) was also highly expressed in
Lrig1+ cells (Figure 5B and Figure S5A). Finally, Lrig1+ cells coex-
pressed Ca2, IL1rn, Apoe, Ccl5, Ccl8, Cd38, and Tst, a subset of
genes upregulated when comparing quiescent to dividing CD34+
cells (Graham et al., 2007) (Figure 5C and Table S3). The lack of
association with cell cycle-promoting genes and the significant
expression of Cdkn1a are consistent with our findings that Lrig1
marks a SC population that is less frequently cycling or is in the
process of downregulating the cell cycle.
Furthermore, general pathway analysis revealed that Lrig1+
cells expressed genes involved in protecting cells from oxidative
damage, as well as a FoxO1 interaction network, which contains
important mediators of SC oxidative stress responses (Tothova
et al., 2007). Expression of Lgr5 is over 20-fold higher in Lgr5+
cells than Lrig1+ cells, and Lrig1 is expressed at modestly higher
levels in Lgr5+ cells (Figure S5A). A subset of geneswas validated
by quantitative real-time PCR (qRT-PCR). These results largely
correlated to the RNA-Seq data; however, we observed discor-
dant results for lowly expressed genes such as mTert (Figures
S5A and S5B). In summary, our whole-transcriptome analysis
data suggest Lrig1+ and Lgr5+ colonic SCs are largely distinctin their mRNA expression profiles and harbor specific gene
expression differences related to cell cycle regulation and oxida-
tive stress responses, possiblymediated throughFoxOsignaling.
Apc Loss in Lrig1+ Cells Results in Dysplastic,
Histologically Advanced Intestinal Adenomas
In the highly dynamic and rapidly renewing intestinal epithelium,
it is thought that SCs, but not transit-amplifying and differenti-
ated cells, have a sufficient lifespan to acquire the number of
mutations required for cancer development (Clarke et al.,
2006). We utilized Lrig1-CreERT2/+;Apcfl/+ mice to examine
whether an initiating event in Lrig1+ cells would result in ‘‘full-
blown’’ tumors (Barker et al., 2009). Upon administration of
tamoxifen, one Apc allele was removed in Lrig1+ cells (Shibata
et al., 1997) (Figure 6A), and tumors arose with stochastic loss
of the second Apc allele (Figure 6J and Figure S6A). We
observed colonic tumors at day 50 by colonoscopy (Figure 6B);
at the time of sacrifice (100 days; n = 17), there were multiple,
distal colonic tumorswith little to no tumor burden in the proximal
colon (Figure 6C–6E). The tumor phenotype was 100% pene-
trant, and the distribution and multiplicity of tumors from seven
mice are shown in Figure 6E; the greatest number of tumors
were observed in the jejunum. The largest tumors were found
in the distal colon, many greater than 2mm in size and with areas
of high-grade dysplasia (Figure 6D and 6F). Immunohistochem-
ical examination of colonic tumors revealed they were highly
proliferative (Ki67 staining in Figure 6G) and, consistent with
loss of Apc (Figure 6J and Figure S6A), harbored large areas of
cytosolic and nuclear b-catenin (Figure 6H and 6I). These tumors
did not exhibit loss of E-cadherin or show invasive properties
(data not shown). Examination of tumors from Lrig1-CreERT2/+;
Apcfl/+;R26RLacZ mice revealed heterogeneous b-gal staining
(Figure S6D), indicating that these tumors may be polyclonal
(Thliveris et al., 2011). No tumors were detected in vehicle-
injected, control mice (data not shown).
Under identical experimental conditions performed concur-
rently, we observed no intestinal tumors in Lgr5-EGFP-IRES-
CreERT2;Apcfl/+ mice (Figures S6B and S6C), as reported
previously (Barker et al., 2009). These results indicate Lrig1+ cells
are long-lived and capable of forming histologically advanced
adenomas following loss of Apc and also provide additional
evidence that Lrig1 marks ISCs.
Ablation of Lrig1 Results in Highly Penetrant Duodenal
Adenomas
Lrig1 is a pan-ErbB negative regulator, prompting us to examine
whether there was a phenotypic consequence in the intestine of
mice in which both Lrig1 alleles were disrupted (homozygous for
Lrig1-CreERT2). As expected, full-length Lrig1 protein was lost in
the small intestine and colon of Lrig1-CreERT2/CreERT2 mice
(Figure S7A). In our examination of Lrig1-CreERT2/CreERT2;
Lgr5-EGFP-IRES-CreERT2 mice that lack Lrig1 but contain the
Lgr5-EGFP reporter, the number of Lgr5-EGFP+ crypts more
than doubled, compared to mice with one or both copies of
Lrig1 (Figure S7D); we also observed an increase in Lgr5 tran-
script expression by qRT-PCR (Figure S7E). These results,
modeled in Figure S7H, support the notion that loss of Lrig1
protein in the SC niche may affect the Lgr5+ population.Cell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc. 151
Figure 5. RNA-Seq Analysis of Lrig1+ and Lgr5+ Cells
(A) Gating strategies for FACS analysis of Lgr5-EGFP-IRES-CreERT2 mouse colonic epithelial cells (n = 5) used to isolate Lrig1+ and Lgr5+ populations (Lrig1-
Alexa568 and Lgr5-EGFPhi, respectively) for RNA-Seq analysis.
(B) FPKM scatter plot depicting representative gene expression profiles of Lrig1+ (y axis) and Lgr5+ (x axis) cells based on Illumina TruSeq V3 RNA-Seq analysis
was conducted and 22,381 gene models are shown. Transcripts detected below 0.5 FPKM in both sample types (likely of little biological significance) are
shown in gray. Red indicates genes significantly overexpressed in Lrig1+ cells compared to Lgr5+ cells; blue indicates genes that are significantly overex-
pressed in Lgr5+ compared to Lrig1+ cells. Transcripts that are significantly expressed but less than 2-fold different between Lgr5+ and Lrig1+ cells are shown in
green. Approximately 2,500 significantly differentially regulated genes are shown (red and blue). Some of the genes discussed in Results are indicated in the
figure.
(C) Abstract network depicting Lgr5- and Lrig1-associated genes in each list that share structural or functional associations, including gene ontology properties,
human disease, andmouse knockout phenotype associations, shared regulatory elements and protein interactions. Significant gene feature associations that are
unique or shared between the two cell compartment gene lists are shown. TFBS is used as an abbreviation for a multispecies conserved transcription factor
binding site. See also Figure S5 and Table S3.In addition, consistent with Lrig1 negative regulation of ErbB
receptors, we detected a significant increase in ErbB1-3 protein
levels and phosphorylated Erk1/2 (pErk1/2) by western blot152 Cell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc.analysis of small intestinal crypt lysates from Lrig1-CreERT2/
CreERT2 mice compared to wild-type mice (Figures 7A and
7B). Of note, Egfr was the most upregulated of the ErbB
Figure 6. Lrig1-CreERT2/+;Apcflox/+ Mice Develop Colonic Tumors
(A) Schematic depiction of experimental design. Mice were injected with tamoxifen daily for 3 days, monitored by colonoscopy starting at day 50 and sacrificed
100 days post-tamoxifen induction.
(B and C) Examination of mice 3 months postinduction revealed the mice developed distal colonic tumors (shown by colonoscopy in B and by whole mount
in C).
(D) Hematoxylin and eosin staining (H&E) staining of a tissue cross-section from a representative colon. Individual tumors are indicated by the asterisks.
(E) Distribution and multiplicity of tumors from seven mice with the greatest number of adenomas formed in the jejunum.
(F) High-grade dysplasia was present within a large tumor (black box in D).
(G–I) Immunohistochemical examination of colonic tumors for Ki67 expression (brown in G), nuclear and cytosolic b-catenin (brown in H), and high-power image
of a gland that contains both cytosolic- and membrane-associated b-catenin (I).
(J) Immunofluorescent examination of colonic tumors for Apc expression (white); Apc expression is heterogeneous.
The scale bars represent 50 mm (F), 25 mm (G, I, and J), and 75 mm (H). The error bars represent SEM. See also Figure S6.receptors. We also observed increased ErbB2 immunoreactivity
in intestinal crypt epithelia of Lrig1-CreERT2/CreERT2 mice
(Figures 7C and 7D).Notably, at 5 to 6 months of age, 14/16 (88%) Lrig1-CreERT2/
CreERT2 mice developed duodenal tumors. Histologically, the
tumors were low-grade adenomas with elongated, crowdedCell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc. 153
Figure 7. Homozygous Lrig1-CreERT2 Mice Exhibit Upregulation of ErbB1-3 and Develop Duodenal Adenomas and Superficially Invasive
Carcinomas
(A) Representative western blot showing increased ErbB1-3 and pErk1/2 levels in crypt epithelium isolated from small intestine of Lrig1-CreERT2/CreERT2
(Cre/Cre) mice compared to wild-type (WT) mice.
(B) Quantification of protein expression levels shown in (A).
(C andD) Immunohistochemical examination of ErbB2 (brown) in intestinal crypts fromWT (C) andCre/Cre (D) mice. Black brackets indicate differential staining at
the crypt base.
(E) Representative H&E staining of an adenoma from a 5-month-old Lrig1-CreERT2/CreERT2 mouse. Tumors exhibited low-grade dysplasia and a marked
plaque-like expansion of Brunner’s glands (n = 14).
(F) One tumor exhibiting histological progression: areas of cribiform architecture and loss of cellular polarity and focal extension of neoplastic glands into deeper
layers of the bowel wall, suggestive of early invasion (inset).
(G) Representative western blot showing increased ErbB1-3 and pErk1/2 levels in tumor (T) compared to gross normal duodenum (N) of Lrig1-CreERT2/
CreERT2 mice.
(H and I) Immunohistochemical examination of pErk1/2 (brown in H) in tumors from Lrig1-CreERT2/CreERT2 mice; boxed region magnified in (I).
(J and K) Immunohistochemical examination of ErbB2 (brown in K) in tumors from Lrig1-CreERT2/CreERT2 mice; boxed region magnified in (J).
The scale bars represent 25 mm (C, D, I, and J), 100 mm (E and F), and 75 mm in (H and K). The error bars represent SEM. See also Figure S7 and
Table S4.nuclei and an increased nuclear-to-cytoplasmic ratio. A distinc-
tive feature was a marked plaque-like expansion of Brunner’s
glands underlying the tumors (Figure 7E). Compared to grossly
normal intestinal epithelium, tumors expressed higher levels
of ErbB1-3 and pErk1/2 observed by western blot analysis
(Figure 7G; quantified in Figure S7B) and higher levels of
pErk1/2 and ErbB2 observed by immunohistochemical analysis
(Figures 7H–7K). By 13 to 14 months of age, 17/19 mice had
duodenal adenomas that were larger and histologically more
advanced than those at 6 months. For example, in one mouse
examined at 13 months of age, the tumor displayed areas of154 Cell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc.cribriform architecture with loss of cellular polarity, indicative of
high-grade dysplasia and focal extension of neoplastic glands
into deeper layers of the bowel wall, suggestive of early invasion
(Figure 7F and inset). Analysis indicated that these tumors
harbored intact Apc (Figure S7C) and did not express nuclear
b-catenin (data not shown), suggesting they arose in a manner
independent of dysregulated canonical Wnt signaling. Taken
together, these data are consistent with a model in which Lrig1
antagonizes ErbB signaling in the intestinal epithelium to main-
tain epithelial homeostasis, and disruption of this negative feed-
back loop can lead to tumor formation.
DISCUSSION
We have identified that the ErbB negative regulator Lrig1 marks
a predominantly quiescent SCpopulation and serves a functional
role in the maintenance of small intestinal and colonic epithelial
homeostasis. Mice lacking Lrig1 develop duodenal tumors, indi-
cating it functions as a tumor suppressor. Our data contribute
to the debate on the complex heterogeneity of ISC populations
and shed light on the relationship between normal ISCs and cells
that give rise to neoplasms in this tissue.
Lrig1 Marks a Distinct Class of Intestinal Stem Cells
Our lineage tracing studies establish that Lrig1 marks both small
intestinal and colonic SCs, and several pieces of evidence
suggest these SCs are distinct from those expressing Lgr5. First,
comparison of Lgr5-EGFP and Lrig1 protein indicates they are
rarely coexpressed in colonocytes (Figure 3 and Figure S4).
Second, Lgr5-EGFP+ cells, but not Lrig1+ cells, are frequently
positive for Ki67 (Figure S4). Moreover, the distinct nature of
Lrig1+ and Lgr5+ SCs is supported by transcriptome profiling.
Lgr5+ cells express many genes associated with cell cycle
promotion, whereas Lrig1+ cells do not, but rather express genes
associated with immune regulation and oxidative stress. These
include genes involved in protecting cells from oxidative
damage, as well as a FoxO1 interaction network, which includes
mediators of oxidative stress responses in other SC systems
(Storz, 2011; Tothova et al., 2007). Notably, Cdkn1a, which is
significantly upregulated in the Lrig1+ cells, is a target of FoxO
signaling (Seoane et al., 2004), suggesting its cell-cycle-repres-
sive properties are linked to the damage response. Interestingly,
it has been shown recently that FoxO factors are required for
maintenance of pluripotency of human embryonic SCs (Zhang
et al., 2011). Although this hypothesis-generating RNA-Seq
analysis offers many leads to pursue, it suggests Lrig1+ cells
repress cell cycle progression and may play a significant role
in oxidative damage responses.
Placing Lrig1+ Stem Cells within a Continuum
of Intestinal Stem Cells
The RNA-Seq data afford an opportunity to compare the relative
expression of other SCmarkers within the Lrig1+ and Lgr5+ pop-
ulations.mTert, Bmi1, and Prominin1 are expressed equivalently
in the two populations. Hopx, recently shown to be a SC marker
in the small intestine, is 2-fold higher in Lgr5+ colonocytes,
consistent with interconversion of Hopx+ and Lgr5+ small intes-
tinal SCs (Takeda et al., 2011). Of interest, the hematopoietic
SC marker Ly6a (Sca-1) (Spangrude et al., 1988) is highly ex-
pressed, specifically in Lrig1+ SCs. The putative SC markers,
Dclk1 and Musashi-1, were expressed at insignificant levels in
both populations under these experimental conditions. Keeping
in mind that the data from our whole-transcriptome analysis are
from an isolated snapshot in time, and thus must be carefully in-
terpreted, our results, as well as a recent report examining coex-
pression of SC markers in the small intestine (Itzkovitz et al.,
2012), support the notion that ISC populations are heteroge-
neous, yet inter-related. We posit that an individual colonic SC
population may have a predominate program (for example, cell
cycle promotion or oxidative stress response) but may becapable of transitioning to or from another state. Thus, expres-
sion of individual SC markers may reflect the cell state, making
each population distinct from others at a given point in time. In
this regard, we show that Lgr5 expression and the number of
Lgr5-EGFP+ crypts significantly increases in Lgr5-EGFP reporter
mice that lack Lrig1 compared to control mice (Figure S7D). It will
be of interest to determine whether Lrig1+ SCs substitute for loss
of Lgr5+ SCs in the colon of Lgr5DTR mice as Bmi1+ SCs do in the
small intestine (Tian et al., 2011). Ultimately what governs these
states and regulates their transitions, during homeostasis and
upon injury, represents a major challenge for ISC biologists.
Using the metrics of proliferation, cell position, and the re-
ported cell number(s) per crypt (Barker et al., 2007; Montgomery
et al., 2011; Sangiorgi and Capecchi, 2008; Takeda et al., 2011;
Tian et al., 2011), we envision that Lrig1+ SCs are downstream
from the more quiescent Bmi1+ or mTert+ SCs, and serve two
roles in homeostasis: (1) to protect the niche from stress and
(2) to give rise to transit-amplifying cells directly and/or to Lgr5
SCs, when needed, as modeled in Figure S7H. We believe the
direct transition from an Lrig1+ SC to an Lgr5+ SC happens infre-
quently aswe rarely observe colocalization of Lrig1 and the Lgr5-
EGFP reporter, and transcriptome analysis indicates the two
populations have a large number of significantly differentially
regulated pathways. Overall, our results, and data from others
(Takeda et al., 2011; Tian et al., 2011), represent initial efforts
to understand how modulation of individual ISC populations
can directly affect the state of others. Going forward,
development of reliable antibodies will facilitate systematic
assessment of ISC populations and how they relate to one
another during homeostasis and in disease states.
LRIG1 in Human Cancer
LRIG1 has a defined role in negative regulation of ErbB recep-
tors, Met (Shattuck et al., 2007) and Ret (Ledda et al., 2008),
to exert control over cell growth. Consistent with this, we
show Lrig1-CreERT2/CreERT2 mice develop duodenal
adenomas by 6 months of age, and these tumors histologically
progress over time, providing the first in vivo evidence that Lrig1
acts as a tumor suppressor (Figure 7). In support of this, LRIG1
is mutated in a subset of colorectal cancers (CRCs) and glio-
blastomas (The Cancer Genome Atlas [TCGA]; see Experi-
mental Procedures). Moreover, LRIG1 expression is downregu-
lated in a number of human tumors, including bladder, lung,
renal, squamous cell, breast, brain, and CRC (Hedman and Hen-
riksson, 2007; Ljuslinder et al., 2007; Miller et al., 2008; Tane-
mura et al., 2005; Thomasson et al., 2003; Ye et al., 2009). It
is important to note that transcriptional and posttranscriptional
regulation of LRIG1 is likely to be complex. For example,
LRIG1 is a candidate for regulation by the miR-17-92 host
gene cluster (via TargetScan, PicTar, and Molecular Signatures
Database analyses; see Experimental Procedures) and the ecto-
domain alone can function independently of full-length protein
to attenuate EGFR signaling (Goldoni et al., 2007). These poten-
tial mechanisms of regulation may result in differential detection
of LRIG1. Consistent with this, we observed variable expression
of LRIG1 in microarray profiling of 100 human CRCs by using
two probe sets that anneal to two different regions of LRIG1.
One probe set is highly expressed, whereas the other isCell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc. 155
downregulated or lost. Variable expression of other intestinal
stem cell markers is also observed (Figure S7F and Table S4).
Similar to this expression profiling data, we observe variable
LRIG1 protein in human CRC; in some cases, it is completely
lost, whereas in others it is strongly expressed at the membrane
(Figure S7G). These observations suggest the tumor suppressor
function of LRIG1 is lost in a subset of CRCs. Further support of
a tumor suppressor role for Lrig1 in intestinal neoplasia comes
from the recent observation that Lrig1 is the most frequently dis-
rupted gene in a subset of adenomas that progress to carci-
noma via a Villin-CreERT2;Kras Sleeping Beauty transposon
system (N. Copeland and N. Jenkins, personal communication).
In summary, we identify the pan-ErbB negative regulator Lrig1
as a functional marker of largely quiescent ISCs and show that it
functions as a tumor suppressor. We propose that Lrig1 contrib-
utes to calibrated ErbB signaling in the ISC niche under homeo-
static conditions and that its loss may contribute to neoplasia.
EXPERIMENTAL PROCEDURES
Mice and Tamoxifen Injection Regimens
The generation of Lrig1 < tm1.1(cre/ERT)Rjc > (Lrig1-CreERT2) mice is
detailed in Figure 1 and the Extended Experimental Procedures. FlpE,
R26RLacZ, and Apcfl/+ mice were obtained from Jackson Laboratory
(Bar Harbor, ME). Lrig1-CreERT2/+ mice were crossed to R26RLacZ mice,
Apcfl/+ mice, or intercrossed within littermates. Lgr5-EGFP-IRES-CreERT2
mice (generously provided by Rune Toftgard and Hans Clevers) were used
alone or crossed to R26RLacZ mice. Duodenum from Lrig1-CreERT2/
CreERT2 mice was processed at between 5 and 13 months of age. Lrig1/
intestinal tissue was generously provided by Colleen Sweeney and prepared
for cryosectioning. For lineage labeling, 6- to 8-week-old Lrig1-CreERT2/+;
R26RLacZ/+ mice were injected (i.p.) once with 2 mg tamoxifen (Sigma) in
corn oil. Lrig1-CreERT2/+;R26R-EYFP mice were injected similarly for 3
consecutive days. For developmental labeling, postnatal day 1 Lrig1-
CreERT2/+;R26RLacZ/+ pups were given a single injection of tamoxifen
(33 mg/kg i.p.) and analyzed as adults. Apcfl/+ mice were crossed to Lrig1-
CreERT2/+ mice; resulting Lrig1-CreERT2/+;Apcfl/+ mice were injected with
tamoxifen once daily (2 mg) for 3 consecutive days and monitored over time
(0–100 days) for tumor formation by colonoscopy. Analysis for Apc loss of
heterozygosity (LOH) details are provided in the Extended Experimental
Procedures. For the injury study, adult Lrig1-CreERT2/+;R26RLacZ/+ mice
were subjected to 8 Gy irradiation 3 months after a single injection of
tamoxifen.
Tissue Preparation for Staining
Tissue preparation and subsequent staining for b-gal activity were performed
as previously described (Li et al., 2004). After taking whole-mount pictures for
b-gal activity, tissues were ‘‘swiss-rolled,’’ dehydrated, paraffin-embedded,
sectioned (10 mm), and counterstained with nuclear fast red (Vector Lab).
For cryosectioning, the tissue was isolated en bloc, processed for subsequent
frozen block preparation and sectioned (5 mm)(Wong et al., 1998). Epithelial
preparation for duodenal western blot analysis was performed as previously
described (Whitehead and Robinson, 2009). Full details are provided in
Extended Experimental Procedures.
Antibodies and Staining Conditions
Immunostaining on frozen sections was performed as previously described
(Davies et al., 2009). EGFP expression was visualized with direct fluorescence.
Primary antibody information for IHC: Mucin 2 (Santa Cruz, sc-15334, 1:100),
Chromogranin-A (Abcam, Ab15160, 1:150), Carbonic Anhydrase IV (R & D,
AF2414, 1:50), Lysozyme (MP Biomedicals, number 11423, 1:100; citrate
buffer antigen retrieval [pH 6]), ErbB2 (Abcam, Ab2428, 1:100), phospho-
p42/44 Erk (Cell Signaling, 1:1000), b-catenin (Transduction lab, 1:1000),
and APC-M2 (Wang et al., 2009) (1:1,000). Sequential staining of YFP and156 Cell 149, 146–158, March 30, 2012 ª2012 Elsevier Inc.Chromogranin-A was performed by first detecting the YFP signal (anti-GFP,
Novus NB600-308, rabbit, 1:4000) with the vector signal amplification kit
(Vector labs, PK-6101), followed by further amplification with TSA-Cy3 system
(Perkin Elmer NEL704A001KT), both according to manufacturer’s instructions.
Slides were then neutralized with Tris-glucose EDTA (25mM Tris-HCl, 10mM
EDTA, 50 mM glucose [pH 9.0]) in the microwave for 7 min, allowing for addi-
tional rabbit antibody detection. Sections were subsequently stained for Chro-
mogranin-A and detected by Alexa-488 secondary antibodies (Molecular
Probes, A11034, 1:400). Cryosections were analyzed for b-gal-expressing
cells by using a polyclonal antibody to b-gal (ICL Laboratories, 1:500) or to
examine Lrig1 expression directly, frozen colon tissue sections were stained
with a polyclonal antibody to Lrig1, made against a mouse N-terminal peptide
KILSVDGSQLKSYC* (cysteine is added to facilitate cross-linking to Keyhole
Limpet Hemocyanin) in collaboration with Covance, Denver PA (1:500). Ki67
was detected with a monoclonal antibody (Dako, 1:250). Fluorescent
secondary antibodies (Jackson Immuno Research Cy3, 1:500 and Cy5,
1:250) were used to detect the primary stains. For colorectal cancer staining,
formalin-fixed, paraffin-embedded tissues were sectioned (10 mm) and stained
with the above-mentioned Lrig1 antibody (1:250).Isolation of Intestinal Epithelium and FACS
Freshly dissected mouse intestine was prepared as described (Powell et al.,
2011); isolated crypts were then collected by slow centrifugation. Crypts
were resuspended in 3% pancreatin solution for 90 min (Whitehead et al.,
1987), pipetted to single cells, and then collected by slow centrifugation. For
FACS, cells were resuspended in Hams F12 media with 1% FCS for Lrig1
staining with Lrig1 antibody (Covance) conjugated to an Alexa-568 fluorophore
(1:250; Molecular Probes). Lgr5+ cells were isolated based on EGFPhi expres-
sion. DAPI (1:10,000; Sigma) was used as a viability marker. Lrig1+ and
Lgr5-EGFP+ cells were isolated with a Becton Dickson FACSAria II using a
100 mm nozzle. Subsequent staining for BrdU was performed with the APC
BrdU Flow kit (BD PharMingen) and BrdU+ cells were analyzed with a Becton
Dickson LSR II. Cell doublets were eliminated on the basis of pulse width.RNA-Seq Analysis
RNA-Seq was conducted with FACS-isolated cells processed with an RNeasy
Mini kit (QIAGEN). The transcriptional sequencing methods were performed
essentially as described (Mortazavi et al., 2008), which is a modification of
the standard Illumina methods (Bentley et al., 2008). Sequencing reactions
were performed with the Illumina HiSeq (v3 chemistry). Full details, as well
as gene set enrichment, feature, biological network analysis, and qRT-PCR,
are provided in Extended Experimental Procedures.Database Analysis
Mutations in LRIG1 in cancer were analyzed by accessing TCGA data
set through the Broad Integrative Genomics Viewer-IGV (http://www.
broadinstitute.org/igv/). Full details regarding the colorectal cancer heat map
are provided in Extended Experimental Procedures and Table S4. MicroRNA
target predictions for Lrig1 were performed with TargetScan, microRNA.org,
PicTar, and Molecular Signatures Database v3.0.ACCESSION NUMBERS
Preprocessed probe intensity scores for the CRC microarray are available
from the Gene Expression Omnibus (GEO) database under accession number
GSE5206.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and four tables and can be found with this article online at
doi:10.1016/j.cell.2012.02.042.
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